S. 2879

To amend the Public Health Service Act to establish programs and activities to address diabetes in children and youth, and for other purposes.

IN THE SENATE OF THE UNITED STATES

July 17, 2000

Ms. Collins (for herself, Mr. Breaux, Mr. Abraham, Mr. Bunning, and Mr. Craig) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To amend the Public Health Service Act to establish programs and activities to address diabetes in children and youth, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Pediatric Diabetes Re-
- 5 search and Prevention Act".

1	SEC. 2. PROGRAMS OF CENTERS FOR DISEASE CONTROL
2	AND PREVENTION.
3	Part B of title III of the Public Health Service Act
4	(42 U.S.C. 243 et seq.) is amended by inserting after sec-
5	tion 317G the following section:
6	"SEC. 317H. DIABETES IN CHILDREN AND YOUTH.
7	"(a) National Registry on Juvenile Diabe-
8	TES.—The Secretary, acting through the Director of the
9	Centers for Disease Control and Prevention, shall develop
10	a system to collect data on type 1 diabetes (or juvenile
11	diabetes), including information with respect to incidence
12	and prevalence, and shall establish a national registry for
13	such data.
14	"(b) Advisory Committee on the National Reg-
15	ISTRY ON JUVENILE DIABETES.—
16	"(1) Establishment.—There is established a
17	committee to be known as the Advisory Committee
18	on the National Registry on Juvenile Diabetes (re-
19	ferred to in this subsection as the 'committee').
20	"(2) Membership.—The committee shall be
21	composed of at least one member, to be appointed
22	by the Secretary, acting through the Director of the
23	Centers for Disease Control and Prevention, rep-
24	resenting each of the following:
25	"(A) Epidemiologists with experience in
26	data registries.

1	"(B) Patients with type 1 diabetes (or ju-
2	venile diabetes), or family members of the pa-
3	tients.
4	"(C) Representatives from nonprofit orga-
5	nizations focused on diabetes research.
6	"(D) Clinicians who have worked with data
7	registries.
8	"(E) Statisticians.
9	"(F) Ethicists.
10	"(G) Attorneys.
11	"(H) Other individuals with an interest in
12	developing and maintaining the registry de-
13	scribed in subsection (a).
14	"(3) Period of appointment; vacancies.—
15	Members shall be appointed for the life of the com-
16	mittee. Any vacancy in the committee shall not af-
17	fect the powers of the committee, but shall be filled
18	in the same manner as the original appointment.
19	"(4) Duties.—The committee shall study, and
20	make recommendations to the Secretary regarding,
21	the development and maintenance of the registry de-
22	scribed in subsection (a).
23	"(5) Powers.—
24	"(A) Hearings.—The committee may
25	hold such hearings, sit and act at such times

and places, take such testimony, and receive such evidence as the committee considers advisable to carry out the objectives of this section.

"(B) Information from federal agen-Cies.—The committee may secure directly from any Federal department or agency such information as the committee considers necessary to carry out the provisions of this section. Upon request of the committee, the head of such department or agency shall furnish such information to the committee.

"(C) Postal services.—The committee may use the United States mails in the same manner and under the same conditions as other departments and agencies of the Federal Government.

"(6) Personnel.—

"(A) TRAVEL EXPENSES.—The members of the committee shall not receive compensation for the performance of services for the committee, but shall be allowed travel expenses, including per diem in lieu of subsistence, at rates authorized for employees of agencies under subchapter I of chapter 57 of title 5, United States Code, while away from their homes or regular

places of business in the performance of services for the committee. Notwithstanding section 1342 of title 31, United States Code, the Secretary may accept the voluntary and uncompensated services of members of the committee.

"(B) Detail of Government employee may be detailed to the committee without reimbursement, and such detail shall be without interruption or loss of civil service status or privilege.

- "(7) PERMANENT COMMITTEE.—Section 14 of the Federal Advisory Committee Act (5 U.S.C.
- 13 App.) shall not apply to the committee.
- "(c) Type 2 Diabetes in Youth.—The Secretary,
 acting through the Director of the Centers for Disease
 Control and Prevention and in consultation with the Administrator of the Health Resources and Services Administration, shall implement a national public health effort
 to address type 2 diabetes in youth, including—
- 20 "(1) enhancing surveillance systems and ex-21 panding research to better assess the prevalence of 22 type 2 diabetes in youth and determine the extent to 23 which type 2 diabetes is incorrectly diagnosed as 24 type 1 diabetes (or juvenile diabetes) among chil-25 dren;

6

7

8

9

10

11

12

1	"(2) assisting States in establishing coordinated
2	school health programs and physical activity and nu-
3	trition demonstration programs to control weight
4	and increase physical activity among youth; and
5	"(3) developing and improving laboratory meth-
6	ods to assist in diagnosis, treatment, and prevention
7	of diabetes including developing noninvasive ways to
8	monitor blood glucose to prevent hypoglycema and
9	improving glucometers that measure blood glucose.
10	"(d) Authorization of Appropriations.—There
11	are authorized to be appropriated to carry out this section
12	such sums as may be necessary for each of fiscal years
13	2001 through 2005.".
14	SEC. 3. PROGRAMS OF NATIONAL INSTITUTES OF HEALTH.
15	Subpart 3 of part C of title IV of the Public Health
16	Service Act (42 U.S.C. 285c et seq.) is amended by insert-
17	ing after section 434 the following section:
18	"SEC. 434A. JUVENILE DIABETES.
19	"(a) Long-Term Epidemiology Studies.—
20	"(1) In general.—The Director of the Insti-
21	tute shall conduct or support long-term epidemiology
22	studies in which individuals with type 1 diabetes (or
23	juvenile diabetes) are followed for 10 years or more.
24	Such studies shall, in order to provide a valuable re-

source for the purposes specified in paragraph (2),

25

- provide for complete characterization of disease manifestations, description of the appropriate medical history, elucidation of environmental factors, delineation of complications, description of results of usual medical treatment, and acquisition of a variety of other potentially valuable information and samples (such as samples of blood).
 - "(2) Purposes.—The purposes referred to in paragraph (1) with respect to type 1 diabetes (or juvenile diabetes) are the following:
 - "(A) Delineation of potential environmental triggers thought to precipitate or cause type 1 diabetes (or juvenile diabetes).
 - "(B) Delineation of clinical characteristics or lab measures associated with complications of the disease.
- "(C) Specification of a potential study population to enter into clinical trials for prevention and treatment, as well as genetic studies.
- 20 "(b) Clinical Trial Infrastructure and Inno-
- 21 VATIVE TREATMENTS FOR JUVENILE DIABETES.—The
- 22 Secretary, acting through the Director of the National In-
- 23 stitutes of Health, shall support regional clinical centers
- 24 for the cure of type 1 diabetes (or juvenile diabetes) and
- 25 shall through such centers provide for—

8

9

10

11

12

13

14

15

16

1	"(1) a well-characterized population of children
2	appropriate for clinical trials;
3	"(2) well-trained clinical scientists able to con-
4	duct such trials;
5	"(3) appropriate clinical settings able to house
6	such trials; and
7	"(4) appropriate statistical capability, data,
8	safety, and other monitoring capacity.
9	"(c) Development of Vaccine.—The Secretary,
10	acting through the appropriate agencies of the Public
11	Health Service, shall provide for a national effort to de-
12	velop a vaccine for type 1 diabetes (or juvenile diabetes).
13	Such effort shall provide for a combination of increased
14	efforts in research and development of candidate vaccines,
15	coupled with appropriate ability to conduct large clinical
16	trials in children.
17	"(d) Authorization of Appropriations.—There
18	are authorized to be appropriated to carry out this section
19	such sums as may be necessary for each of fiscal years
20	2001 through 2005.".

 \bigcirc